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Available online 14 November 2015Background: Vitamin E δ-tocotrienol (VEDT), a natural vitamin E from plants, has shown anti-neoplastic and che-
moprevention activity in preclinical models of pancreatic cancer. Here, we investigated VEDT in patients with
pancreatic ductal neoplasia in awindow-of-opportunity preoperative clinical trial to assess its safety, tolerability,
pharmacokinetics, and apoptotic activity.
Methods: Patients received oral VEDT at escalating doses (from 200 to 3200mg) daily for 13 days before surgery
and one dose on the day of surgery. Dose escalation followed a three-plus-three trial design. Our primary end-
points were safety, VEDT pharmacokinetics, and monitoring of VEDT-induced neoplastic cell apoptosis
(ClinicalTrials.gov number NCT00985777).
Findings: In 25 treated patients, no dose-limiting toxicity was encountered; thus no maximum-tolerated dose
was reached. One patient had a drug-related adverse event (diarrhea) at a 3200-mg daily dose level. The effective
half-life of VEDTwas ~4 h. VEDT concentrations in plasma and exposure proﬁles were quite variable but reached
levels that are bioactive in preclinical models. Biological activity, deﬁned as signiﬁcant induction of apoptosis in
neoplastic cells as measured by increased cleaved caspase-3 levels, was seen in the majority of patients at the
400-mg to 1600-mg daily dose levels.
Interpretation: VEDT from 200 to 1600 mg daily taken orally for 2 weeks before pancreatic surgery was well tol-
erated, reached bioactive levels in blood, and signiﬁcantly induced apoptosis in the neoplastic cells of patients
with pancreatic ductal neoplasia. These promising results warrant further clinical investigation of VEDT for
chemoprevention and/or therapy of pancreatic cancer.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Pancreatic ductal adenocarcinoma (PDA) is a highly lethal form of
pancreatic malignancy (Hidalgo, 2010; Siegel et al., 2013, 2015). Late
detection, when cure is rare, underscores the signiﬁcant need to devel-
op novel early detection, prevention, and treatment strategies for PDA.
No chemoprevention agent exists for pancreatic cancer, and less than
5 potential pancreatic cancer chemoprevention agents have so far
entered early-phase clinical trials (Stan et al., 2010).
The cancer preventive activity of vitamin E has been under intense
investigation for decades (Ling et al., 2012). Among the eight forms ofy, H. Lee Mofﬁtt Cancer Center
33612, USA.
lafa).
. This is an open access article undervitamin E (alpha-, beta-, gamma-, and delta-tocopherol and alpha-,
beta-, gamma-, and delta-tocotrienol), alpha-tocopherol has been stud-
ied in two large epidemiological chemoprevention trials with disap-
pointing results. In the Women's Health Study trial, women who
received alpha-tocopherol every other day had the same chance of
developing lung, breast, or colon cancer as those given the placebo
(Lee et al., 2005). Similarly, in the selenium, vitamin E, and prostate
cancer chemoprevention trial (completed in 2008), alpha-tocopherol
consumption, alone or in combination with selenium, was found to
have no signiﬁcant effect in reducing prostate cancer incidence
(Lippman et al., 2009). These negative results could be because the
type of vitamin E used was not bioactive for cancer prevention. In con-
trast to the mostly inconsistent results with alpha-tocopherols,
tocotrienols (Fig. 1) have shown positive chemopreventive effects in
preclinical animal carcinogenesis models (colon, prostate, mammary,
and lung) (Gould et al., 1991; Iqbal et al., 2004; Ngah et al., 1991;the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chemical structures of tocopherols and tocotrienols are similar in that they both contain an aromatic ring chromanol ring to which the free radical scavenging hydroxyl moiety is
attached. The main difference between tocopherols and tocotrienols is in the saturation of the aliphatic side chain attached to the chromanol ring. The aliphatic side chain is saturated in
tocopherols and unsaturated in tocotrienols. The 4 isomers (alpha, beta, gamma, delta) are named for speciﬁc methyl group substitutions at positions 5, 7, and 8 of the chromanol ring.
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evidence of anticancer activity in humans is lacking.
Recently, we demonstrated that vitamin E δ-tocotrienol (VEDT) pre-
vents pancreatic carcinogenesis in the K-ras transgenic mouse model
(Husain et al., 2013a). This form has shown apoptogenic activity previ-
ously (Birringer et al., 2003). Also, using the more aggressive K-ras-p53
transgenic mouse model of pancreatic carcinogenesis, we showed that
VEDT prolonged mouse survival by preventing pancreatic cancer
growth and metastasis (Husain et al., 2013b). We also showed that
VEDT's anticancer activity in pancreatic neoplasia was associated with
selective induction of apoptosis in pancreatic transformed and malig-
nant epithelial cells but not in normal immortalized human pancreatic
ductal epithelial cells (Hodul et al., 2013; Husain et al., 2011).
Here,we aimed to translate our preclinicalﬁndings in a phase I dose-
escalation trial of VEDT in pancreatic cancer patients, with the primary
objective of determining the VEDT dose that exhibits biologic activity
in humans. In particular, we sought to identify the dose that selectively
induces apoptosis in malignant pancreatic tissue and to characterize
VEDT pharmacokinetic properties and its safety and tolerability. The
systematic measurement of pharmacodynamic endpoints in trials of
signaling agents in pancreatic cancer is hampered by the limited quan-
tity of patient tissue that can be obtainedwith ﬁne-needle aspiration bi-
opsies. Thus, we employed a presurgical trial design in which patients
with pancreatic ductal neoplasia who had indications for surgical resec-
tion of their tumors consumed VEDT for a brief period of time immedi-
ately preceding the day of surgery. Finally, the patient's entire tumor
was resected along with adjacent non-malignant pancreatic tissue,
thus yielding abundant tissue for pharmacodynamic analyses.
2. Methods
This study was a single-center, open-label, dose escalation phase I
trial (ClinicalTrials.gov NCT00985777) in patients with presumptive
premalignant (intraductal papillary mucinous neoplasm or mucinous
cystic neoplasm of the pancreas) or malignant (pancreatic carcinoma)
neoplasms of the exocrine pancreas having indications for curative sur-
gical resection. Presumptive premalignancy was detected by computed
tomography or endoscopic ultrasonography. All patients providedwrit-
ten informed consent on a protocol approved by the University of South
Florida Institutional Review Board.
2.1. Patient Population
Inclusion criteria included age ≥ 18 years, Eastern Cooperative
Oncology Group (ECOG) performance status of b2, serum creatininelevel b 1.5 mg/dL or calculated creatinine clearance N 60 mL/min, total
bilirubin b 2.0 mg/dL, alanine aminotransferase and aspartate
aminotransferase b 2.5 times the upper limit of normal, absolute neu-
trophil count N 1000 mm3, and platelet count N 50,000/mm3. Patients
with borderline resectable PDA were not eligible. Exclusion criteria in-
cluded having had radiation therapy, chemotherapy, or investigational
therapy or had major surgery within 30 days before the ﬁrst dose of
study drug. Patients with active infection or fever N38.5 °C within
3 days of ﬁrst dose of study drug or with uncontrolled intercurrent ill-
ness were ineligible. An uncontrolled intercurrent illness is one that de-
velops in a patient between clinical assessment visits and then becomes
uncontrolled (that is, medical therapy has become ineffective).
2.2. Treatment and Dose Escalation
We gave patients the study drug orally as a single agent twice daily
for 13 consecutive days before surgery and one dose on the day of sur-
gery (day 14). The formulation consisted of 99% pure VEDT encapsulat-
ed into soft gels, where the soft gel comprises pharmaceutical-grade
medium-chain triglyceride. BED was deﬁned as the maximum-
tolerated dose (MTD) of VEDT that demonstrates signiﬁcant induction
of apoptosis in the neoplastic cells from resected tumor samples of our
treated patients. Because this micronutrient might not exhibit dose-
limiting toxicity (DLT) beyond its BED, dose escalation was stopped at
3200mgdaily ifMTDwas not reached. Using the body-surface area nor-
malizationmethod frommice to human, we estimated 3200mgdaily to
be 5.6 times the predicted BED. If biological effect was seen at lower
doses, we planned to continue to dose escalate to MTD to investigate
dose-related increases in biological effect.
Patients were treated in cohorts of three starting at our initial dose
level (100 mg twice daily). Subsequent cohorts were escalated to 200,
300, 400, 800, and 1600 mg twice daily. Patients were instructed to
take VEDTwith a full glass of water (~8 oz) after eating a light breakfast
except on day 14when VEDTwas takenwithwater only. On day 14, pa-
tients had standard pancreatectomy. We did not allow intra-patient
dose escalation.
2.3. Toxicity Evaluation
Wegraded adverse events according to theNational Cancer Institute
Common Terminology Criteria for Adverse Events version 4·0. The safe-
ty analysis included all patients who received at least one dose of VEDT.
Adverse events were recorded at each visit and, if related to VEDT, were
followed to resolution. Laboratory assessments, including hematology,
were done pretreatment and on days 1, 8, and 14.
Table 1
Patient characteristics (N = 25).
No. Percentage
Age, years
Mean 65.3
Range 49–84
Sex
Male 16 64
Female 9 36
Ethnicity
White 21 84
Black 3 12
Unknown 1 4
Histologic type
Ductal adenocarcinoma 10 40
Intraductal papillary mucinous 7 28
Invasive mucinous carcinoma 1 4
Mucinous cystic neoplasm 2 16
Pancreatic intraepithelial neoplasia 3 8
Squamoid cyst 1 4
Serous cystadenoma 1 4
1989G.M. Springett et al. / EBioMedicine 2 (2015) 1987–19952.4. Pharmacokinetics
Blood samples were collected on 1) day 1 pre-dose and post-dose at
30min and at 1, 2, 4, 6, and8 h; 2) day 2 pre-dose; 3) day8 pre-dose and
post-dose at 4 h; 4) day 13 pre-dose and post-dose at 30min and at 1, 2,
4, 6, and 8 h; and 5) day 14 post-dose.
VEDT concentrations were determined in plasma and tissue by liq-
uid chromatography. Our methods were validated according to ICH/
FDA guidelines. Calibration and quality control (QC) samples were
made by adding known amounts of VEDT to plasma or tissue. All cali-
bration, QC, and unknown patient samples were prepared as follows:
VEDT was extracted from plasma using protein precipitation with a
mixture of acetonitrile and tetrahydrofuran, followed by taking the ex-
tracts to solid-supported liquid extraction plates. Elution from plates
was carried out by hexane. Tissue was treated with a combination of
ethanol, water, and hexane, and extraction was aided by homogeniza-
tion, with hexane layer then captured. Plasma and tissue extracts in
hexane were evaporated to dryness. Concentrated samples were
reconstituted with 110 μL hexane to ready them for injection.
Samples were injected into an Agilent Technologies (Palo Alto, CA)
1100/1200 liquid chromatography system coupled to a ﬂuorescence
detector. A Zorbax (Agilent) pure silica, normal-phase chromatographic
column was used for separation. The mobile phase was
hexane:isopropanol (99:1), and ﬂow rate was set to 0.65 mL/min. The
ﬂuorescence detector was set at an excitation wavelength of 296 nm
and emission wavelength of 330 nm to capture chromatographic
peaks of interest.
Chromatographic peaks were integrated by Agilent Technologies
Chemstation software (version B.03.02). Linear regression was used to
form the calibration curve from calibration standards; QCs were
checked against the regression line, and unknowns were plotted for
back calculation of the patients' raw concentrations. The calibration of
VEDT is linear in plasma from 5 to 1000 ng/mL and from 5 to 1000 ng/
100 mg of tissue. Inter- and intra-assay variabilities were b11%, with a
relative mean error of b9.4%.
Raw concentration data from HPLC assays were used to formulate
pharmacokinetic data for VEDT. The area under the curve (AUC) for
the dosing interval (AUC0− T), AUC to inﬁnity, maximum concentration
(Cmax) and time to maximum concentration (Tmax), volume of distri-
bution, and clearance were determined for VEDT on day 1. Non-
compartmental methods were applied to determine pharmacokinetic
parameters, and segmented AUC between samples was determined by
the trapezoid rule.
2.5. Pharmacodynamics
The apoptotic effect of VEDT in pancreatic tumors was assessed by
caspase-3 activation in the neoplastic cells of treated patients,
determined by immunohistochemistry. Histology slides stained
against antibodies to caspase-3 were scanned using the Aperio™
(Vista, CA) ScanScope XT with a 200×/0.75NA objective lens at a rate
of 3 min/slide via Basler tri-linear-array. Immunopositivity of caspase-
3 was quantitatively scored using commercial algorithms from the Pos-
itive Pixel Count v9 Aperio Toolbox®, which used scored staining inten-
sities for pixels as follows: 3+, strong; 2+, moderate; 1+, weak; 0,
negative. Staining intensities were thresholded by the 0–255 8-bit dy-
namic range value (220, 175, and 100, respectively). This algorithm
was optimized by a board-certiﬁed pathologist (BAC) and applied to
speciﬁc regions identiﬁed by the pathologist. Twenty-ﬁve total ﬁelds
of view were counted to calculate the number of caspase-3-positive
cells. On average, 3051 cells were counted for neoplastic cells and 485
for non-neoplastic cells. We used only cells that had a 3+ or 2+ stain-
ing intensity as caspase-3-positive cells tomaintain a high threshold for
scoring apoptosis induction.
To establish the threshold for signiﬁcant induction of apoptosis in
pancreatic neoplastic tissue, we examined archival surgical tumorspecimens from 20 patients without VEDT treatment. These 20 patients
who did not receive VEDT comprised our control group, with their pan-
creatic neoplasms resected by the same surgeon who performed resec-
tions of the treated patients over the same period as treated patients.
Results show the following frequency distribution of the percentage of
caspase-3-positive cells in the untreated neoplastic tissue: 0th percen-
tile: 0.3%; 50th percentile: 2.1%; 90th percentile: 7.6%; 100th percentile:
11.6% (mean 3.3% and SD 3.3). The majority of VEDT untreated tumor
samples had caspase-3-positive cells b2.1%. We used a conservative
threshold of the 90th percentile, 7.6%, as the threshold to determine
the biological response. This high threshold is likely to minimize the
false-positive rate.
2.6. Statistical Analyses
Patient demographics, adverse events, and clinical laboratory evalu-
ationswere categorized descriptively. Quantitative laboratorymeasure-
ments such as pharmacokinetic parameterswere summarized asmeans
and SD. For evaluation of caspase-3 expression, complete permutation
test was used to test any group differences for each two-group compar-
ison, because data were skewed with many zeros and the sample size
was in a manageable scale (n b 50).
3. Results
3.1. Patient Characteristics
Between September 2009 and May 2012, 19 patients were enrolled,
with 18 treated. One patient was withdrawn before treatment due to
the development of duodenal obstructive symptoms. An additional
seven patients were treated at the expansion dose (800 mg daily).
Patient characteristics are summarized in Table 1.
3.2. Safety and Tolerability
VEDTwaswell tolerated at all dose levels. No drug-related toxicities
were seen at 200–1600 mg daily. At 3200 mg daily, one patient had
two episodes of drug-related grade 1 diarrhea (Table 2). Ten patients
(including three dose-escalation (800mg) patients) from the expansion
cohort were used to evaluate safety and efﬁcacy (biological effect re-
sponse). Two metrics were evaluated: serious adverse event (SAE)
rate and adverse event (AE) rate. We considered a dose to be tolerable
if the SAE rate was b30% and the AE rate was b50%. The lower bounds
(8% and 20%, respectively) of the 95% CI for the 30% SAE and the 50%
AE toxicity rates were used for determination.
Table 2
Treatment-related adverse events (grades I to IV) in all patients.
200 mg
(n = 3)
400 mg
(n = 3)
600 mg
(n = 3)
800 mg
(n = 3)
Expansion Cohort,
800 mg (n = 7)
1600 mg
(n = 3)
3200 mg
(n = 3)
Fatigue 0 0 0 0 0 0 0
Weight loss 0 0 0 0 0 0 0
Bruising 0 0 0 0 0 0 0
Pruritus 0 0 0 0 0 0 0
Rash 0 0 0 0 0 0 0
Wound complication 0 0 0 0 0 0 0
Anorexia 0 0 0 0 0 0 0
Constipation 0 0 0 0 0 0 0
Dehydration 0 0 0 0 0 0 0
Diarrhea 0 0 0 0 0 0 2
Abdominal bloating 0 0 0 0 0 0 0
Flatulence 0 0 0 0 0 0 0
Other GI 0 0 0 0 0 0 0
Nausea 0 0 0 0 0 0 0
Vomiting 0 0 0 0 0 0 0
UTI 0 0 0 0 0 0 0
Hyperglycemia 0 0 0 0 0 0 0
Hypoglycemia 0 0 0 0 0 0 0
Mental status change 0 0 0 0 0 0 0
Pain 0 0 0 0 0 0
1990 G.M. Springett et al. / EBioMedicine 2 (2015) 1987–1995There were 0 SAEs and 0 AEs in the 10 patients who received
800 mg; these rates were lower than the lower bounds (8% and 20%)
of the 95% CI for the 30% and 50% rates, respectively. In addition, in
our evaluated patients (n = 25), only one drug-related AE was noted
in one patient at the 1600-mg dose (4% AE rate, which is again lower
than the lower bounds). We concluded that VEDT was statistically
conﬁrmed to be safe and tolerable at all of the doses tested with 95%
conﬁdence.3.3. Pharmacokinetics
Pharmacokinetic analyses were conducted in the ﬁrst 18 patients.
We found substantial interpatient variability in pharmacokinetic pa-
rameters at all dose levels (Table 3). The possibility that this could be re-
lated to variability in the composition of themeal consumed by patients
was considered. Therefore, the meal with the morning VEDT dose was
standardized. Nevertheless, interpatient variability continued to be ob-
served. Beyond 400mg daily, there was no clear dose-proportionate re-
lationship to Cmax and AUC (Fig. 2A). For all patients treated, Tmaxwas
5.6±2.1 h and half-lifewas 3.8±1.8 h (Table 3). For patients treated at
≥400mg daily, mean Cmaxwas 2111± 1940 ng/mL or 5.32± 4.89 μM,
a concentration level comparable to that seen in patients dosed with
mixed tocotrienols (Yap et al., 2001). It is also in the concentration
range seen in mouse plasma dosed orally with VEDT (Husain et al.,
2013a). This plasma concentration level of VEDT has been demonstrat-
ed to have antitumor activity in preclinical models (Husain et al., 2009).
Furthermore, the AUC observed in humans is consistent with the AUC
observed with the bioactive dosing in mice (Husain et al., 2009) and
in cell culture (Fig. 2B).Table 3
Pharmacokinetic parameters for VEDT by dose level.
Dose level (mg daily) No. Cmax (ng/mL) AUC0–12 (ng × h/mL) A
Mean SD Mean SD M
200 3 178.1 67.4 3157.4 1750.1
400 3 1299.5 790.8 13,486.9 9499.0 1
600 2 2818.5 2511.1 10,707.7 9111.8 1
800 3 1882.1 1505.8 12,503.2 9898.8 1
1600 3 4141.8 2717.2 27,424.6 16,631.3 3
3200 3 2585.1 1733.6 13,291.6 5198.5 1
AUC = area under the serum concentration curve; Cmax = peak serum concentration; t1/2 =3.4. Biological Activity
First, we compared the levels of cleaved caspase 3 in control samples
from untreated patients with samples from the patients treated in the
six dose-escalation cohorts. We expected to see increased caspase-3-
positive cells in tumor tissues from treated but not from untreated
patients, and also likely not in normal tissues from treated patients.
Before analyses, samples from the dose-escalation patient cohorts
were grouped into “treated normal” and “treated dysplastic or malig-
nant” tissues. As shown in pairwise comparisons in Fig. 3, control
tumor tissues from untreated patients had comparable percentages of
caspase-3-positive cells to normal tissues from treated patients (adjust-
ed P = 0.725). In contrast, control tumor tissues from untreated
patients had a statistically signiﬁcant difference (lower) compared
with dysplastic or malignant tissues from treated patients (adjusted
P = 0.005). Moreover, the dysplastic or malignant tissues had a higher
percentage of caspase-3-positive cells than the normal tissues from
the same treated patients (adjusted P = 0.011). These results suggest
that caspase-3 is a good biomarker to evaluate the biological effect of
VEDT.
Next, we investigated the biological effect response in the six dose-
escalation cohorts, using the threshold of 7.6% to evaluate each patient
(n = 16 patients). As shown in Fig. 4, the percentage of caspase-3-
positive cells increased for patients given 200–600 mg and then de-
creased for patients given 800–3200 mg daily. The biological response
rate had a similar pattern, starting with 50%with 200mg, then increas-
ing 100%with 400 and 600mg, and then decreasing to 66%with 800mg
and 1600 mg and to 33% with 3200 mg.
Because we wanted to identify a high dose level with a high biolog-
ical effect response rate (N50%), we considered the 800- and 1600-mgUC0 − ∞ (ng × h/mL) t1/2 (hours) Clearance (L/h) Vd (L)
ean SD Mean SD Mean SD Mean SD
3024.1 2461.9 2.0 0.5 49.5 40.3 235.9 192.2
4,300.9 9785.2 5.5 0.5 38.2 24.0 317.0 218.2
2,292.7 7150.2 2.9 1.5 29.4 17.1 141.1 136.2
3,436.1 9473.4 2.9 2.0 39.5 21.2 195.9 208.3
7,340.8 24,810.6 3.9 1.9 40.1 42.4 151.1 74.5
6,692.6 7434.3 5.4 1.6 106.4 47.4 890.5 614.6
half-life; Vd = volume of distribution.
Fig. 2. VEDT reaches bioactive levels in human serum. a: Large variability in pharmacokinetic parameters is shown, with peak VEDT serum levels (Cmax) of up to 18 μM and AUC up to
170 μM. b:MTT assay of VEDT treatment of MiaPaCa-2 and L3.6 pl human PDAC cells in vitro demonstrates IC50 of 5 and 10 μMwith 5-day treatment.
1991G.M. Springett et al. / EBioMedicine 2 (2015) 1987–1995dose levels for the expansion cohort to investigate BED. We elected to
start with the 800-mg daily dose.
Ten patients (including three patients in the dose-escalation cohort)
were used to evaluate biological effect response. A biological effect re-
sponse rate N 50% would be considered a BED. The upper bound
(79.9%) 95% CI for a 50% response rate was used for determination. As
shown in Fig. 5, the 800-mg dose yielded an 80% (8/10) biological effect
response rate, which was higher than the upper bound (79.9%) of the
95% CI for a 50% response rate. These results indicate that 800 mg
could be selected as a BED.
Finally, we compared control samples from untreated patients to
samples from treated patients from the dose-escalation plus expansion
cohorts. As shown in pairwise comparisons (Fig. 6), untreated control
tumor tissues had comparable percentage of caspase-3-positive cells
to the ‘treated normal’ tissues (adjusted P = 0.985), with a statistically
signiﬁcant difference (lower) versus treated dysplastic or malignantFig. 3.Apoptosis in untreated control pancreatic ductal malignant cells comparedwith VEDT-tre
index, as measured by % cells staining positive for caspase-3 in untreated control malignant cel
VEDT-treated patients on the same period of time was low. Moreover, the apoptotic index of t
ductal epithelial cells in VEDT-treated patients (P= 0.725). In contrast, the apoptotic index of th
those of the untreated control malignant cells (P= 0.005). Moreover, the apoptotic index of the
epithelial cells (P = 0.011). These ﬁndings strongly suggest selective induction of apoptosis intissues (adjusted P=0.044).Moreover, the treateddysplastic or treated
malignant tissues had a higher percentage of caspase-3-positive cells
than treated normal tissues (adjusted P= 0.044). Both treated dysplas-
tic and treated malignant tissues had a similar higher percentage of
caspase-3-positive cells (P = 0.985). We therefore concluded that the
800-mg dose was statistically conﬁrmed to be a BED with 95% conﬁ-
dence and therefore stopped further accrual.
4. Discussion
Our study conﬁrmed the safety and tolerability of highly pure VEDT
(99%) at doses up to ﬁve times greater than those given to patients in
previous studies, which used a mixture of tocotrienols (Rahmat et al.,
1993; Qureshi et al., 1995, 2002; Zaiden et al., 2010). The relatively
short time to Tmax and half-life of pure VEDT are similar to results re-
ported with lower doses of mixed tocotrienols (Qureshi et al., 1995,ated pancreatic ductal normal and neoplastic (dysplastic ormalignant) cells. The apoptotic
ls in patients (n = 20) with PDAC operated on by the same surgeon who operated on the
hese malignant cells was not statistically different from the apoptotic index of the normal
e VEDT-treated neoplastic cells (Dysplastic andMalignant) were signiﬁcantly higher than
VEDT-treated neoplastic cells was also signiﬁcantly higher than the VEDT-treated normal
neoplastic cells by VEDT treatment.
Fig. 4. Biologic evidence of tumor response. a:Waterfall plot of the best biologic response to VEDT at different doses in patients at the escalation doses. Red line represents statistically
calculated threshold of signiﬁcant induction of apoptosis (7.6%). b: Immunohistochemistry sections from pancreatectomy specimens stained with hematoxylin and eosin (×20 magniﬁ-
cation), as well as for cleaved caspase-3 (×20 magniﬁcation), highlighting biologic responses in representative patients. Both invasive mucinous adenocarcinoma and adjacent normal
specimens are shown at two VEDT dose levels: 100 mg (Patient 1) and 200 mg (Patient 4). Arrows in normal specimens indicate normal duct or normal duct cells negative for
caspase-3. For Patient 1, arrows in invasive specimens indicate mucinous adenocarcinoma (H&E slide) or carcinomatous epithelium (caspase-3 slide). For Patient 4, arrows in invasive
specimens indicate malignant gland (H&E slide) or cells undergoing apoptosis based on caspase-3 expression (caspase-3 slide).
1992 G.M. Springett et al. / EBioMedicine 2 (2015) 1987–19952002; Zaiden et al., 2010). The fact that levels in the plasma did not cor-
relatewellwith administered dose suggests that there are factors affect-
ing the metabolism and circulation of this nutrient that remain
unknown. Nevertheless, the concentrations obtained in plasma in thisstudy are comparable to those obtained in mice treated with VEDT in
which tumor growth was delayed and apoptosis was induced (Husain
et al., 2009). The ﬁnding that pancreatic tumors from several patients
treated with VEDT displayed much higher percentages of apoptotic
Fig. 5. Biologic response in the expansion cohort. Apoptotic index asmeasured by % cells staining positive for caspase-3 was used to assess biologic response in the expansion cohort. Ten
patients (including three patients in the dose-escalation cohort) were treated at the 800-mg dose level; 80% (8/10) patients had signiﬁcant induction of apoptosis in their dysplastic or
malignant tissue. Red line indicates threshold of biological response (7.6%).
1993G.M. Springett et al. / EBioMedicine 2 (2015) 1987–1995tumor cells than those from untreated patients suggests that plasma
levels obtained may be sufﬁcient to have the desired biological effect.
The challenge now is to understand why some patients treated at aFig. 6. Pairwise comparison of apoptotic index in untreated control versus VEDT-treated patien
comparable percentage of caspase-3-positive cells to the “treated normal” tissues (adjusted P=
lignant tissues (adjusted P= 0.044). Treated dysplastic or treatedmalignant tissues had a highe
Both treated dysplastic and treated malignant tissues had a similar higher percentage of caspahigher dose failed to show a higher percentage of apoptotic tumor
cells. This could be due to tumor genetic heterogeneity, altered suscep-
tibility to the biological effect of VEDT, or intrinsic variability amongt in both the dose-escalation and expansion cohorts. Untreated control tumor tissues had
0.985), with a statistically signiﬁcant difference (lower) versus treated dysplastic or ma-
r percentage of caspase-3-positive cells than treated normal tissues (adjusted P= 0.044).
se-3-positive cells (P = 0.985).
1994 G.M. Springett et al. / EBioMedicine 2 (2015) 1987–1995individuals in the metabolism and clearance of the drug at high doses.
Higher concentrations could also modulate other cellular targets,
which counteract the VEDT pro-apoptotic effects.
Regarding dose, our selection was designed to ensure the greatest
margin of safety and to focus on identifying the biologic effective dose
as deﬁned by biological activity in tumor samples. Our starting dose
(100 mg twice a day) was based on the rationale described in the
Food and Drug Administration (FDA) guidance “General Guide for
Starting Dose Selection for a Cytotoxic Agent in Cancer Patients” (avail-
able at www.fda.gov/cder/cancer/docs/doseﬂow.pdf) as well as on the
no-observed-adverse-effect level (NOAEL) determined in a published
repeat-dose toxicity study in rats (Nakamura et al., 2001). In this
13-week toxicity study, the NOAELs for VEDT were concluded to
be 0.19% in the diet (120 mg/kg body weight/day for male rats and
130 mg/kg body weight/day for female rats). The human equivalent
doses based on equivalent relative body surface areas of 1:6:2 will
yield 19.4 mg/kg/day dosed daily for up to 13 weeks. Therefore, for a
65-kg subject the NOAEL dose of VEDT will be 1261 mg/day.
In mice, VEDT dosed at 100 mg/kg/day once daily (via oral gavage)
resulted in signiﬁcant inhibition of tumor growth and induction of apo-
ptosis in the neoplastic cells. Using the recommended body surface area
(BSA) normalization method for allometric dose translations when
starting new clinical studies (Reagan-Shaw et al., 2008), the formula
below was used: Human Equivalent Dose (mg/kg) = Animal dose
(mg/kg) × Animal Km / Human Km (where Km values based on body
surface area for a mouse is 3 and an adult human is 37 (60 kg)).
Converting a dose of VEDT (100 mg/kg) given to a mouse into
the human equivalent dose based on body surface area is: HED =
100 (mg/kg) × 3 (mouse Km) / 37 (Human Km); The HED =
8.11 mg/kg. A 70 kg subject would therefore require 567 mg/day.
Dose escalation to amaximumof 3200mg/daywill be 5.6 times the pre-
dicted bioactive dose from the preclinical studies.
The ability of VEDT to induce apoptosis in pre-malignant lesions
(dysplastic tissue) but not in adjacent normal tissue has particular
promise for pancreatic cancer prevention. Pancreatic carcinogenesis is
a multistep process that involves the accumulation of a set of genetic
changes that convert normal cells ﬁrst to premalignant cells and then
to malignant cells (Iacobuzio-Donahue, 2012; Iacobuzio-Donahue
et al., 2012). In a recent study, an average of 63 mutations per cancer
was altered in 24 human PDAs (Jones et al., 2008). The most widely ac-
cepted explanation for the accumulation of multiple mutations in the
same cell is the model of clonal evolution, when cells with one crucial
mutation expand clonally (Aparicio and Caldas, 2013). By increasing
in number through mitosis and suppression of apoptosis, cells with
the ﬁrst mutation become more likely to develop a second mutation,
which predisposes to a third mutation and so on. The continuing clonal
expansion, selection, and heterogeneity allow accumulation of multiple
mutations in the same cell and the ultimate generation of malignant
clones (Iacobuzio-Donahue, 2012). Therefore, reducing or eliminating
the number of premalignant cells could be an effective strategy to re-
duce pancreatic cancer risk (Wu and Lippman, 2011). One intriguing
ﬁnding demonstrated consistently by us and others is the selective kill-
ing effect of tocotrienols against cancer cells over normal cells (Hodul
et al., 2013; Husain et al., 2011; Srivastava and Gupta, 2006; Yap et al.,
2008, 2010). Tocotrienol was found to induce apoptosis in prostate
and breast cancer cells but not in nonmalignant breast and prostate ep-
ithelial cells (Srivastava and Gupta, 2006; Yap et al., 2008, 2010). Be-
cause no effective chemoprevention therapy for the medical treatment
of pre-malignant pancreatic lesions is available, patients face the choice
of potentially life-changing pancreatectomy versus observation with
the risk of transformation to invasive adenocarcinoma and metastasis.
In addition, no effective surveillance strategies are available to identify
transformation before metastasis. The ability of VEDT to induce apopto-
sis in the neoplastic cells of intraductal papillary mucinous neoplasm
and pancreatic intraepithelial neoplasia lesions with minimal toxicity
establishes this micronutrient as a candidate chemoprevention agentfor the medical treatment of patients with these lesions who opt to
not have surgery. The tolerability of VEDTwith longer-term administra-
tion of high doses will be the subject of future investigation.
The survival beneﬁt of our intervention is unknown. This was a
proof-of-concept biologic endpoint trial, where the goal was to demon-
strate induction of apoptosis in patient tumors after a 2-week exposure
to VEDT in thepreoperative setting. Enhancement of survivalwasnot an
anticipated or stated endpoint. Its effect on survival outcomes is a
subject for a phase II efﬁcacy trial.
In conclusion, this ﬁrst-in-human phase I study of VEDT was de-
signed to establish the BED of VEDT for future investigations of the clin-
ical activity of VEDT. VEDT is distinguished fromother tocotrienols by its
consistently superior anticancer activity in preclinical models. Although
there are no approved agents for pancreatic cancer prevention, the dis-
mal natural history of pancreatic cancer and increasing recognition of
high-risk individuals warrants the investigation of promising agents
like VEDT from preclinical studies (Husain et al., 2013a). Here, we
have shown that VEDT use in untreated patients with pancreatic cancer
andhigh-risk premalignant tumorswas associatedwith selective induc-
tion of apoptosis in neoplastic cells without toxicity. These results, as
well as efﬁcacy data of VEDT in preclinical studies, encourage our fur-
ther exploration of VEDT as an alternative treatment for patients at
risk of pancreatic cancer. Additional considerations of VEDT include its
use in treatment of early-stage disease to prevent or delay relapse, as
well as combining VEDT with chemotherapy and other targeted agents.
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